Ken Fisher Vertex Pharmaceuticals Inc Transaction History

Fisher Asset Management, LLC

$229 Billion
Q2 2024

A detailed history of Ken Fisher (Fisher Asset Management, LLC) transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Fisher Asset Management, LLC holds 28,105 shares of VRTX stock, worth $13.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

28,105

Previous 27,523 2.11%

Holding current value

$13.3 Million

Previous $11.5 Million 14.51%

% of portfolio

0.01%

Previous 0.01%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$392.81 - $485.53 $228,615 - $282,578	582 Added 2.11%	28,105 $13.2 Million
Q1 2024 May 09, 2024	BUY	$407.69 - $446.08 $343,682 - $376,045	843 Added 3.16%	27,523 $11.5 Million
Q4 2023 Mar 05, 2024	BUY	$343.0 - $410.68 $77,518 - $92,813	226 Added 0.85%	26,680 $10.9 Million
Q4 2023 Feb 06, 2024	BUY	$343.0 - $410.68 $37,044 - $44,353	108 Added 0.41%	26,454 $10.8 Million
Q3 2023 Nov 13, 2023	SELL	$338.18 - $362.46 $1.05 Million - $1.13 Million	-3,118 Reduced 10.58%	26,346 $9.16 Million
Q2 2023 Dec 12, 2023	BUY	$314.42 - $351.91 $976,274 - $1.09 Million	3,105 Added 11.79%	29,451 $10.4 Million
Q2 2023 Aug 08, 2023	BUY	$314.42 - $351.91 $934,141 - $1.05 Million	2,971 Added 11.21%	29,464 $10.4 Million
Q1 2023 Dec 12, 2023	BUY	$283.23 - $323.1 $307,871 - $351,209	1,087 Added 4.13%	27,433 $8.64 Million
Q1 2023 May 01, 2023	BUY	$283.23 - $323.1 $120,089 - $136,994	424 Added 1.63%	26,493 $8.35 Million
Q4 2022 Feb 03, 2023	BUY	$285.76 - $321.48 $138,879 - $156,239	486 Added 1.9%	26,069 $7.53 Million
Q3 2022 Nov 08, 2022	SELL	$273.83 - $305.53 $183,466 - $204,705	-670 Reduced 2.55%	25,583 $7.41 Million
Q2 2022 Aug 09, 2022	BUY	$234.96 - $292.55 $392,148 - $488,265	1,669 Added 6.79%	26,253 $7.4 Million
Q1 2022 May 05, 2022	SELL	$221.42 - $260.97 $152,115 - $179,286	-687 Reduced 2.72%	24,584 $6.42 Million
Q4 2021 Feb 02, 2022	BUY	$177.01 - $223.45 $204,800 - $258,531	1,157 Added 4.8%	25,271 $5.55 Million
Q3 2021 Oct 26, 2021	SELL	$181.39 - $202.99 $163,069 - $182,488	-899 Reduced 3.59%	24,114 $4.37 Million
Q2 2021 Jul 27, 2021	SELL	$187.49 - $221.1 $194,989 - $229,944	-1,040 Reduced 3.99%	25,013 $5.04 Million
Q1 2021 Apr 27, 2021	BUY	$207.02 - $241.31 $253,806 - $295,846	1,226 Added 4.94%	26,053 $5.6 Million
Q4 2020 Jan 29, 2021	BUY	$207.01 - $276.09 $73,074 - $97,459	353 Added 1.44%	24,827 $5.87 Million
Q3 2020 Nov 10, 2020	BUY	$255.65 - $303.1 $294,253 - $348,868	1,151 Added 4.94%	24,474 $6.66 Million
Q2 2020 Aug 07, 2020	SELL	$225.48 - $295.8 $96,505 - $126,602	-428 Reduced 1.8%	23,323 $6.77 Million
Q1 2020 Apr 28, 2020	BUY	$199.77 - $247.81 $279,278 - $346,438	1,398 Added 6.25%	23,751 $5.65 Million
Q4 2019 Feb 12, 2020	BUY	$166.71 - $223.91 $38,009 - $51,051	228 Added 1.03%	22,353 $4.89 Million
Q3 2019 Oct 29, 2019	BUY	$166.23 - $187.09 $45,879 - $51,636	276 Added 1.26%	22,125 $3.75 Million
Q2 2019 Jul 30, 2019	BUY	$164.61 - $190.37 $1.1 Million - $1.27 Million	6,660 Added 43.85%	21,849 $4.01 Million
Q1 2019 Apr 22, 2019	BUY	$163.73 - $194.7 $2.09 Million - $2.49 Million	12,768 Added 527.39%	15,189 $2.79 Million
Q4 2018 Jan 25, 2019	BUY	$151.91 - $192.21 $33,875 - $42,862	223 Added 10.15%	2,421 $401,000
Q3 2018 Oct 24, 2018	SELL	$167.73 - $192.74 $871,692 - $1 Million	-5,197 Reduced 70.28%	2,198 $424,000
Q1 2018 Apr 19, 2018	BUY	$151.6 - $177.13 $349,589 - $408,461	2,306 Added 45.31%	7,395 $1.21 Million
Q4 2017 Jan 24, 2018	BUY	$137.28 - $155.55 $14,414 - $16,332	105 Added 2.11%	5,089 $763,000
Q3 2017 Oct 17, 2017	BUY	$148.13 - $162.24 $738,279 - $808,604	4,984	4,984 $758,000

Others Institutions Holding VRTX

# of Institutions

1,719

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $121B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track Ken Fisher's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.

Account